Redwood City, CA, United States

OncoMed Pharmaceuticals

www.oncomed.com
Redwood City, CA, United States

Time filter

Source Type

Patent
OncoMed Pharmaceuticals | Date: 2017-01-11

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.


Patent
OncoMed Pharmaceuticals | Date: 2017-06-21

The present invention relates to RSPO-binding agents, particularly antibodies that specifically bind human RSPOl. Also described are methods of treating cancer and other diseases, comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient in need thereof.


Patent
OncoMed Pharmaceuticals | Date: 2016-10-12

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.


Patent
OncoMed Pharmaceuticals | Date: 2017-03-22

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2017-02-08

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly gastric cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit growth of a gastric tumor. Also described are methods of treating gastric cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a gastric tumor or gastric cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-10-20

The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.


Patent
OncoMed Pharmaceuticals | Date: 2017-07-26

The present invention relates to RSPO and LGR antagonists, and methods of using the RSPO and LGR antagonists for treating or preventing fibrotic diseases. The present invention provides methods for treating a fibrotic disease in a subject, where the methods include administering to a subject a therapeutically effective amount of a RPSO and/or LGR antagonist, such as an anti-RSPO antibody, an anti-LGR antibody, or a soluble LGR receptor. The present invention also provides methods of treating or preventing a fibrotic disease in a subject, comprising administering to the subject a therapeutically effective amount of a LGR-binding agent, including any of those described herein.


Patent
OncoMed Pharmaceuticals | Date: 2017-07-05

The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.


Patent
OncoMed Pharmaceuticals | Date: 2017-08-09

The present invention relates to agents that modulate the Hippo pathway and Hippo pathway signaling, such as antibodies, soluble receptors, polypeptides, peptides, and small molecules. The invention relates to methods of screening for and/or identifying such agents and methods of using the agents for the treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-05-27

Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.

Loading OncoMed Pharmaceuticals collaborators
Loading OncoMed Pharmaceuticals collaborators